

## Technology Advisory Committee B Interests Register

### Pembrolizumab for adjuvant treatment of renal cell carcinoma [ID3810]

Publication Date: 19/10/2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Nick Latimer	Committee Member	Non-financial professional and personal	I am a member of the SchARR team for a research project investigating methods for adjusting for treatment switching in clinical trials, funded by Merck, Sharpe and Dohme. This is not drug or appraisal specific and is about developing methods. Merck, Sharpe and Dohme are the manufacturer.		12/05/22 13/07/22		It was agreed that this declaration would not prevent Professor Latimer from taking part in this discussion
Ms Sophie-Ann Scott	Patient expert	Indirect financial	My organisation - Kidney cancer UK - has received funding from Pfizer Merck and BMS for various projects.	14/09/21	12/05/22 13/07/22		It was agreed that this declaration would not prevent Sophie-Ann Scott from providing expert advice during this discussion.
Dr Natalie Charnley	Clinical expert	Direct financial	I have received meeting sponsorship from BMS, Ipsen and Eusa, and speaker fees from Pfizer and Ipsen and I	27/04/22	12/05/22 13/07/22		It was agreed that these declarations would not prevent Dr Charnley from providing expert advice in this discussion

		Indirect financial interest	<p>have received research sponsorship from BMS.</p> <p>(Kidney Cancer UK) has received funding from BMS, Merck and Pfizer.</p>				
Professor Thomas Powles	Clinical expert	<p>Direct financial interest</p> <p>Indirect financial interest</p>	<p>I have received remuneration by MSD for my work on advisory boards</p> <p>I have sat on advisory/research boards (honorary) for the following pharmaceutical companies: AstraZeneca, BMS, Exelixis, Incyte, Ipsen, Merck, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson &amp; Johnson, Eisai, and Roche. I received travel/accommodation expenses from the following pharmaceutical companies: Roche, Pfizer, MSD, AstraZeneca, Ipsen, and my institution has received grants/funding from AstraZeneca, Roche, BMS, Exelixis, Ipsen, Merck, MSD,</p>	<p>12/05/22</p> <p>27/09/21</p>	<p>12/05/22</p> <p>13/07/22</p>		It was agreed that these declarations would not prevent Professor Powles from providing expert advice during this discussion.

		Direct non-financial interest	<p>Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson &amp; Johnson, Eisai.</p> <p>I have received academic credit for satellite symposia, co-leading the pembrolizumab study and leading on a number of trials for MSD.</p>	12/05/22			
--	--	-------------------------------	---	----------	--	--	--